Determination of long-acting release octreotide, an octapeptide analogue of in human plasma by liquid somatostation, chromatography/tandem mass spectrometry

被引:15
作者
Jiang, Yao [1 ]
Wang, Jiang [1 ]
Wang, Yingwu [1 ]
Du, Xiaolin [1 ]
Zhang, Yunhui [1 ]
Fawcett, J. Paul [3 ]
Gu, Jingkai [1 ,2 ]
机构
[1] Jilin Univ, Coll Life Sci, Res Ctr Drug Metab, Changchun 130023, Peoples R China
[2] Jilin Univ, Minist Educ, Key Lab Mol Enzymol & Engn, Changchun 130021, Peoples R China
[3] Univ Otago, Sch Pharm, Dunedin, New Zealand
关键词
D O I
10.1002/rcm.3293
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A sensitive and selective method for the determination of long-acting released octreotide in human plasma has been developed based on liquid chromatography/tandem mass spectrometry (LC/MS/ MS). Octreotide and the internal standard, triptorelin, were precipitated from the matrix, washed with dichloromethane and subsequently separated by reversed-phase high-performance liquid chromatography (HPLC) employing a 1% formic acid/methanol gradient system. Detection was by electrospray ionization mass spectrometry in the positive ion mode using multiple-reaction monitoring. The assay was linear in the concentration range 0.0500-50.0 ng/mL with intra- and inter-day precision (as relative standard deviation) of <2.95% and <8.37%, respectively. The limit of detection was 0.0200 ng/mL. The method was applied to a pharmacokinetic study of long-acting released octreotide in healthy volunteers given an intramuscular injection containing 20 mg octreotide. Copyright (C) 2007 John Wiley & Sons, Ltd.
引用
收藏
页码:3982 / 3986
页数:5
相关论文
共 13 条
[1]   Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles [J].
Astruc, B ;
Marbach, P ;
Bouterfa, H ;
Denot, C ;
Safari, M ;
Vitaliti, A ;
Sheppard, M .
JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (07) :836-844
[2]  
Ding Jin-song, 2004, Yaoxue Xuebao, V39, P542
[3]   The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: Comparison with standard subcutaneous octreotide therapy [J].
Dogliotti, L ;
Tampellini, M ;
Stivanello, A ;
Gorzegno, G ;
Fabiani, L .
ANNALS OF ONCOLOGY, 2001, 12 :S105-S109
[4]   DETERMINATION OF METHYLEUGENOL IN RODENT PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
GRAVES, SW ;
RUNYON, S .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1995, 663 (02) :255-262
[5]   EFFECT OF SUBCUTANEOUS INJECTION OF A LONG-ACTING ANALOG OF SOMATOSTATIN (SMS-201-995) ON PLASMA THYROID-STIMULATING HORMONE IN NORMAL HUMAN-SUBJECTS [J].
ITOH, S ;
TANAKA, K ;
KUMAGAE, M ;
TAKEDA, F ;
MORIO, K ;
KOGURE, M ;
HASEGAWA, M ;
HORIUCHI, T ;
WATABE, T ;
MIYABE, S ;
SHIMIZU, N .
LIFE SCIENCES, 1988, 42 (26) :2691-2699
[6]  
LEMAIRE M, 1989, DRUG METAB DISPOS, V17, P699
[7]   Confirmatory analysis for drugs of abuse in plasma and urine by high-performance liquid chromatography-tandem mass spectrometry with respect to criteria for compound identification [J].
Maralikova, B ;
Weinmann, W .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2004, 811 (01) :21-30
[8]  
MARBACH P, 1985, ADV EXP MED BIOL, V188, P339
[9]  
Murty SB, 2004, AAPS PHARMSCITECH, V5
[10]   Evaluation of matrix effect and chromatography efficiency: New parameters for validation of method development [J].
Rogatsky, E ;
Stein, D .
JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY, 2005, 16 (11) :1757-1759